List of Excipients in Branded Drug LORATADINE 10MG

Generic Drugs Containing LORATADINE 10MG

Company	Ingredient	NDC	Excipient
MARKSANS PHARMA LIMITED	loratadine 10mg	25000-092	LACTOSE MONOHYDRATE
MARKSANS PHARMA LIMITED	loratadine 10mg	25000-092	MAGNESIUM STEARATE
MARKSANS PHARMA LIMITED	loratadine 10mg	25000-092	MICROCRYSTALLINE CELLULOSE 101

What are the Most Frequently-Used Excipients in LORATADINE 10MG?

# Of NDCs	Excipient
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE
1	MICROCRYSTALLINE CELLULOSE 101

Loratadine 10 mg Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Loratadine 10 mg is a mature, low-cost OTC antihistamine with limited active-ingredient patent protection and intense generic competition. Commercial differentiation depends on dosage-form performance, taste, convenience, stability, packaging, and channel economics rather than exclusivity. The highest-value opportunities are orally disintegrating tablets, chewables, pediatric liquids, low-sugar formulations, fast-dissolution tablets, and differentiated combination products.

What is the regulatory and commercial status of loratadine 10 mg?

Loratadine is a second-generation H1 antihistamine used for allergic rhinitis and chronic urticaria. The standard adult and pediatric dose for patients aged 6 years and older is 10 mg once daily. FDA OTC labeling permits tablets, chewable tablets, and oral liquid products when the applicable requirements are met [1].

Attribute	Loratadine 10 mg position
Active ingredient	Loratadine
Therapeutic class	Second-generation antihistamine
Primary indications	Allergic rhinitis, hay fever, chronic urticaria
Standard dose	10 mg once daily
Common age range	Adults and children 6 years and older
Original innovator	Schering-Plough, later associated with Bayer’s Claritin business
Prescription-to-OTC transition	Approved for OTC marketing in the 1990s
Current market	Highly genericized OTC market
Biosimilar exposure	None
Primary differentiation	Formulation, taste, convenience, packaging, price, and channel access

The reference product is Claritin 10 mg. Major competitors include store-brand loratadine tablets, chewables, orally disintegrating tablets, and liquids sold by retailers, pharmacy chains, and private-label manufacturers.

What patents protect loratadine 10 mg?

The original loratadine compound patent estate is expired. The principal historical U.S. patent associated with loratadine was U.S. Patent No. 4,282,233, covering piperidine derivatives including loratadine-related compounds. Its effective term ended many years ago [2].

Patent category	Commercial relevance
Original loratadine compound patent	Expired
Basic tablet formulation patents	Generally expired or commercially nonblocking
Loratadine-pseudoephedrine combinations	Historical patents largely expired
Orally disintegrating formulations	Potentially relevant only if a new, non-obvious composition or process is claimed
Taste-masking systems	Potentially protectable, but scope depends on formulation specificity
Manufacturing processes	May be protectable if they reduce impurities, improve yield, or control particle properties
Packaging and delivery systems	Usually limited protection and easy to design around

A new loratadine product should not rely on the active ingredient for exclusivity. Any defensible intellectual-property position would need to arise from a specific excipient combination, manufacturing process, delivery system, or combination product.

What is the Orange Book status of loratadine 10 mg?

Loratadine products have limited practical Orange Book significance because most 10 mg products are sold under OTC pathways rather than as newly protected prescription products. Legacy NDA listings may remain relevant for reference-product identification, but they do not create meaningful market exclusivity for a standard generic loratadine tablet.

The key regulatory distinction is between:

1. Products marketed under an FDA OTC monograph.
2. Products associated with legacy approved applications.
3. Private-label or store-brand products manufactured under contract.

FDA’s current OTC framework for antihistamines is set out in 21 C.F.R. Part 341 and related FDA monograph materials [1,3]. A sponsor should evaluate whether the proposed dosage form and labeling fit the monograph conditions or require an approved application.

How should excipients be selected for loratadine 10 mg tablets?

Loratadine is a poorly water-soluble compound. Tablet performance therefore depends heavily on particle size, wetting, granulation, disintegration, and dissolution. The excipient system should be selected around rapid release rather than simply tablet hardness or low manufacturing cost.

Conventional immediate-release tablet

A standard 10 mg tablet can use:

• Microcrystalline cellulose as a diluent and dry binder.
• Lactose monohydrate, mannitol, or dibasic calcium phosphate as additional fillers.
• Croscarmellose sodium, crospovidone, or sodium starch glycolate as superdisintegrants.
• Povidone or copovidone as a binder where wet granulation is used.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate or sodium stearyl fumarate as a lubricant.
• Film-coating polymers such as hypromellose, polyethylene glycol, talc, and titanium dioxide where permitted.

A direct-compression platform offers the lowest process cost but requires tight control of loratadine particle size, blend uniformity, segregation, and lubricant sensitivity. Wet granulation can improve content uniformity and flow but adds drying costs and increases the risk of process-related variability.

The preferred development sequence is usually:

1. Screen loratadine particle size and specific surface area.
2. Compare direct compression with dry granulation.
3. Optimize superdisintegrant level and lubricant concentration.
4. Establish dissolution targets under discriminatory conditions.
5. Confirm stability under heat and humidity.

Excipient risks in conventional tablets

Excess magnesium stearate can slow wetting and dissolution. High levels of hydrophobic glidants can produce the same effect. Over-compression can delay disintegration, particularly when the formulation uses a low level of superdisintegrant.

Lactose provides a low-cost filler but can create compatibility or labeling issues for certain consumer segments. Mannitol improves mouthfeel and is useful in chewable and orally disintegrating products, but it increases formulation cost. Dibasic calcium phosphate improves tablet robustness but is less attractive for very rapid dissolution.

What excipients are best for loratadine orally disintegrating tablets?

Orally disintegrating tablets, or ODTs, offer one of the strongest opportunities for product differentiation. They target consumers who have difficulty swallowing, need portability, or prefer administration without water.

A practical loratadine ODT platform may include:

Formulation function	Candidate excipients
Primary filler	Mannitol, lactose, microcrystalline cellulose
Rapid disintegration	Crospovidone, croscarmellose sodium
Taste masking	Ion-exchange resin, polymer coating, cyclodextrin, coated API
Binder	Povidone, copovidone, low-substituted hydroxypropyl cellulose
Sweetener	Sucralose, aspartame, acesulfame potassium
Flavor	Orange, grape, berry, mint, or fruit blends
Saliva wetting	Poloxamer or selected surfactant systems
Flow aid	Colloidal silicon dioxide
Lubricant	Magnesium stearate or sodium stearyl fumarate

The principal technical challenge is taste. Loratadine has a bitter sensory profile, and rapid disintegration increases exposure of the drug in the mouth. A formulation that disintegrates quickly but has poor taste can fail commercially even if it meets dissolution specifications.

Taste masking can use coated loratadine particles, resin complexes, polymeric barriers, or a combination of sweetener and flavor. Each option affects dissolution, tablet size, compressibility, and cost. A coated-particle approach offers stronger sensory control but may create a potential formulation patent position if the coating composition and process are novel.

An ODT product should be evaluated for:

• Disintegration time.
• In-mouth texture.
• Residual grittiness.
• Bitter aftertaste.
• Mechanical strength.
• Friability.
• Moisture sensitivity.
• Packaging protection.
• Dose uniformity.
• Dissolution after taste-masking treatment.

Blister packaging may provide better moisture protection than bottles but raises packaging cost. Unit-dose blister packs are commercially attractive for travel and convenience channels.

What excipients are suitable for loratadine chewable tablets?

Chewable tablets can provide a lower-cost alternative to ODTs while offering strong sensory differentiation. Mannitol is commonly attractive because it produces a cooling sensation and clean mouthfeel. Sorbitol can improve sweetness and chewability but may create gastrointestinal tolerance concerns at high exposure.

A chewable loratadine formulation can combine:

• Mannitol for bulk and mouthfeel.
• Sorbitol or xylitol for sweetness and texture.
• Crospovidone for breakup after chewing.
• Sucralose or acesulfame potassium for high-intensity sweetness.
• Flavor oils or spray-dried flavors.
• Colloidal silicon dioxide for flow.
• Sodium stearyl fumarate where lower hydrophobicity is desirable.

The commercial opportunity is strongest in pediatric and family allergy products. The formulation must avoid excessive tablet hardness, chalkiness, sticking, and flavor fade during shelf life.

What excipients are suitable for loratadine oral liquids?

Loratadine’s limited water solubility makes oral liquid development more complex than tablet development. A suspension may be simpler than a true solution, but it requires particle-size control, wetting, sedimentation control, redispersibility testing, and preservative performance.

Potential liquid excipient categories include:

Function	Candidate excipients
Vehicle	Purified water, glycerin, propylene glycol, sorbitol solution
Wetting agent	Polysorbate 80 or other compatible surfactant
Suspending agent	Xanthan gum, microcrystalline cellulose and carboxymethylcellulose, sodium carboxymethylcellulose
Buffer	Citrate or phosphate system
Sweetener	Sucrose, sorbitol, sucralose
Preservative	Sodium benzoate, potassium sorbate, or another permitted system
Flavor	Fruit flavor systems
Chelator	Disodium EDTA where justified

A sugar-free liquid can target diabetic and health-conscious consumers, but sorbitol and glycerin levels must be controlled for viscosity and gastrointestinal tolerability. Preservative selection should be supported by antimicrobial effectiveness testing. The product also needs a clear dose-measuring device, preferably a calibrated oral syringe or dosing cup.

The main commercial weakness of liquid loratadine is higher manufacturing, shipping, and packaging cost. Its value is concentrated in pediatric, institutional, and caregiver-directed channels.

What manufacturing and formulation IP barriers exist?

The strongest potential IP positions are likely to involve formulation engineering rather than loratadine itself.

Potentially protectable areas

• Specific taste-masked loratadine particles.
• ODT compositions with defined disintegration and dissolution profiles.
• Low-moisture formulations with improved stability.
• High-load, direct-compression formulations.
• Particle-engineering processes that improve dissolution.
• Pediatric liquids with improved suspension stability.
• Unit-dose delivery systems.
• Loratadine combinations with decongestants or other allergy medicines.

A patent claim directed only to “loratadine plus a conventional filler and disintegrant” would face substantial novelty and obviousness risk. Stronger claims would define measurable performance, a narrow excipient ratio, a particular coating architecture, or a process that produces a non-obvious technical result.

Freedom-to-operate analysis should include U.S., European, Canadian, Japanese, Australian, and selected emerging-market patent records. The active-ingredient estate is not the primary barrier. Private formulation patents, trademarks, packaging rights, and manufacturing know-how may matter more.

When does loratadine 10 mg lose exclusivity?

Loratadine lost meaningful compound exclusivity more than two decades ago. Generic and private-label competition is established across major markets.

Exclusivity element	Status
Compound exclusivity	Expired
Standard 10 mg tablet exclusivity	Expired or unavailable
OTC market access	Available subject to applicable FDA requirements
Generic entry risk	Very high for conventional tablets
Formulation-specific entry risk	Depends on patent claims and process complexity
Biosimilar risk	Not applicable
Brand premium	Sustained mainly through recognition, convenience, packaging, and distribution

A new entrant should assume rapid price competition in standard tablets. A premium position requires a differentiated consumer benefit that is visible at the point of purchase.

Which commercial opportunities are most attractive?

1. Private-label conventional tablets

This is the lowest-risk opportunity but also the most commoditized. Success depends on reliable supply, low cost per tablet, retailer relationships, and packaging flexibility. Contract manufacturing scale is more important than formulation novelty.

2. ODT and fast-dissolving products

ODTs can command a premium over basic tablets if taste, mouthfeel, and moisture protection are strong. The best targets are travel, convenience, older consumers, and consumers with swallowing difficulty.

3. Pediatric chewables and liquids

Pediatric products can support higher margins because flavor, dosing devices, and caregiver convenience reduce direct price comparison. Products should align with FDA age labeling and avoid unnecessary excipient complexity.

4. Sugar-free and allergen-positioned products

Sugar-free, lactose-free, gluten-free, and dye-free positioning can support niche retail placement. These claims must be substantiated through the complete formulation and labeling review.

5. Combination allergy products

Loratadine-pseudoephedrine products, including extended-release formats, address nasal congestion as well as allergy symptoms. They carry greater regulatory, supply, abuse-control, and formulation complexity. Pseudoephedrine sales restrictions and state-level requirements can constrain distribution.

6. Emerging-market supply

Loratadine is suitable for high-volume markets where seasonal allergy prevalence and OTC access are expanding. Local manufacturing, bilingual packaging, climate-stable formulations, and low-cost blister packs can improve competitiveness. Registration requirements, permitted excipients, labeling language, and local reference-product rules vary by country.

How does loratadine compare with competing antihistamines?

Product	Key commercial attribute	Formulation opportunity
Loratadine	Low sedation perception, once-daily dosing, mature generic supply	ODT, chewable, pediatric liquid, low-cost private label
Cetirizine	Strong allergy positioning, but greater sedation concern for some users	Fast-dissolving and liquid products
Fexofenadine	Non-sedating positioning and premium brand history	High-dose tablets and combination products
Desloratadine	Active metabolite of loratadine with differentiated branding	Higher-dose and prescription-to-OTC positioning where permitted
Diphenhydramine	Low cost but sedating	Limited premium opportunity
Levocetirizine	Strong efficacy positioning	Pediatric and convenience dosage forms

Loratadine’s advantage is manufacturing familiarity and broad consumer recognition. Its weakness is the absence of meaningful compound-level exclusivity and the large number of substitutable antihistamines.

What patent litigation and Paragraph IV risks affect loratadine?

Paragraph IV litigation risk is low for the basic loratadine 10 mg product because the principal compound and standard dosage-form patents are expired. New litigation risk would arise mainly from a later formulation patent, combination product, delivery system, or branded product with a separately protected technical feature.

For a conventional generic tablet, the principal legal risks are:

• Misclassification under the OTC framework.
• Labeling or active-ingredient compliance issues.
• Trade-dress or trademark disputes.
• Formulation patent claims asserted against a specific product.
• Manufacturing-site or supplier-related regulatory deficiencies.

There is no biosimilar pathway because loratadine is a small-molecule drug. A sponsor should treat formulation patents as product-specific rather than assuming that all loratadine products share the same legal profile.

What is the revenue exposure for a loratadine 10 mg launch?

Revenue exposure is highly sensitive to the selected segment.

Product strategy	Revenue potential	Margin potential	Main risk
Basic tablet	High volume	Low	Immediate price erosion
Chewable	Moderate volume	Moderate	Taste and texture failure
ODT	Moderate volume	Moderate to high	Moisture and taste performance
Pediatric liquid	Lower volume	Moderate	Stability and preservative performance
Combination product	Moderate	Moderate to high	Regulatory and supply complexity
Private-label retailer program	High volume	Low to moderate	Buyer concentration

A conventional tablet can support scale but rarely supports durable premium pricing. An ODT or chewable platform can create greater gross margin if the consumer benefit is clear and manufacturing yield remains high.

Key Takeaways

• Loratadine 10 mg is a mature OTC product with expired compound exclusivity.
• Standard tablets are highly commoditized and face immediate generic and private-label price pressure.
• Excipient strategy should prioritize dissolution, content uniformity, manufacturability, taste, and moisture stability.
• Mannitol, crospovidone, croscarmellose sodium, coated API particles, and carefully selected sweetener-flavor systems are central to differentiated ODT and chewable products.
• Oral liquids offer pediatric and caregiver opportunities but carry higher stability and manufacturing costs.
• The most defensible new IP is likely to involve taste masking, particle engineering, controlled disintegration, moisture protection, or manufacturing processes.
• Biosimilar risk is irrelevant because loratadine is a small molecule.
• The strongest commercial opportunities are ODTs, chewables, pediatric liquids, sugar-free products, private-label supply, and selected combination products.
• Standard generic tablets remain attractive only when supported by low manufacturing cost, reliable supply, and retailer access.

FAQs

Can loratadine 10 mg be formulated as an orally disintegrating tablet without water?

Yes. An ODT can be designed to disintegrate on the tongue using mannitol, a superdisintegrant, taste-masked loratadine particles, sweeteners, and flavor. Moisture-protective packaging is usually important.

Which excipient creates the greatest formulation risk in loratadine tablets?

The main risk is not one excipient but excessive hydrophobicity in the formulation. High lubricant levels, poor wetting, large API particles, and over-compression can delay dissolution.

Is a loratadine suspension commercially superior to a loratadine solution?

Not necessarily. A suspension may be easier to develop because loratadine has limited water solubility, but it requires sedimentation, redispersibility, dose-uniformity, and preservative control.

Can a new loratadine formulation obtain patent protection?

Yes, but protection must generally rest on a specific, non-obvious composition, process, delivery system, or measurable technical effect. A basic mixture of loratadine with routine tablet excipients is likely to face a weak patent position.

Does loratadine 10 mg have a biosimilar market?

No. Loratadine is a chemically synthesized small molecule. Competition occurs through generic, OTC monograph, private-label, and branded products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M012: Antihistamine drug products for over-the-counter human use. FDA.
2. U.S. Patent No. 4,282,233. (1981). Piperidine derivatives. U.S. Patent and Trademark Office.
3. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. FDA.
4. DailyMed. (2024). Loratadine tablet and orally disintegrating tablet labeling. U.S. National Library of Medicine.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.